Atorvastatin News and Research

RSS

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Reimbursement systems appear to impact on achievement of cholesterol lowering targets

Dr Gitt said: "There are wide variations between European countries in the achievement of LDL-cholesterol (LDL-C) targets. However the effect of different reimbursement systems on meeting the targets was unknown."

2 Sep 2013

Study finds that high potency statins can beat dementia

Dr Lin said: "Statins are widely used in the older population to reduce the risk of cardiovascular disease. But recent reports of statin-associated cognitive impairment have led the US Food and Drug Administration (FDA) to list statin-induced cognitive changes, especially for the older population, in its safety communications."

2 Sep 2013

Genetic variations in genes could put patients at risk for statin-associated muscle injury: Study

Statins, a class of drugs used to lower cholesterol, are among the best selling drugs in North America and around the world. However, statin myopathy, which results in muscle pain and weakness, is a common side effect affecting up to 10 percent of statin users. A recent study led by Dr. Richard Kim of the Lawson Health Research Institute, in collaboration with Dr. Robert Hegele of Robarts Research Institute, and researchers from Vanderbilt University, found that commonly occurring genetic variations in a person's genes could put them at risk for statin-associated muscle injury.

7 Aug 2013

Stopping cholesterol drugs may increase risk of Parkinson's disease

People who stop taking cholesterol drugs may be at an increased risk for developing Parkinson's disease, according to research that appears in the July 24, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

25 Jul 2013

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.

4 May 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013

Coenzyme Q10 offsets cellular changes that are linked to side-effect of some statin drugs: Study

A laboratory study has shown for the first time that coenzyme Q10 offsets the cellular changes that are linked to a side-effect of some statin drugs - an increased risk of adult-onset diabetes.

11 Apr 2013

Study evaluates efficacy of drug combinations in treating colorectal cancer

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Once colorectal cancer has spread to other parts of the body, only 11 percent of patients will survive five years from the date of their diagnosis.

8 Apr 2013

High-dose rosuvastatin reduces acute kidney injury caused by imaging dye in ACS patients

High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

12 Mar 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

FDA acknowledges resubmission of Merck’s NDA for ezetimibe and atorvastatin tablets

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine.

3 Jan 2013

Monoclonal antibody boosts cholesterol reduction

Adding a monoclonal antibody that blocks the breakdown of lipid receptors to atorvastatin therapy further reduces low-density lipoprotein cholesterol levels in patients with primary hypercholesterolemia, show study findings.

9 Nov 2012

Monoclonal antibody boosts cholesterol reduction

6 Nov 2012

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2012.

1 Nov 2012

Intensive treatment with high doses of statin drugs shows promise for dyslipidemia

A comprehensive new review on how to treat high cholesterol and other blood lipid problems suggests that intensive treatment with high doses of statin drugs is usually the best approach.

16 Oct 2012

Meijer offers generic Lipitor for free to help families be heart healthy

In an effort to help families be heart healthy, this week Midwest retailer Meijer began offering the generic substitute for Lipitor (atorvastatin calcium) for free in all 199 Meijer pharmacies.

4 Sep 2012

Statin's potency may cause muscle problems in patients with cardiovascular disease

A study from the University of California, San Diego School of Medicine, published August 22 online by PLoS ONE, reports that muscle problems reported by patients taking statins were related to the strength or potency of the given cholesterol-lowering drugs.

23 Aug 2012

Dr. Reddy's launches generic LIPITOR tablets in the U.S.

Dr. Reddy's Laboratories announced today that it has launched ATORVASTATIN CALCIUM TABLETS 10 mg, 20 mg, 40 mg and 80 mg, a bioequivalent generic version of LIPITOR (atorvastatin calcium) tablets, in the US market on July 17, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for atorvastatin calcium tablets.

18 Jul 2012

Individuals on statins more likely to experience fatigue with exertion

In a study of more than 1,000 adults, researchers at the University of California, San Diego, found that individuals taking cholesterol-lowering statin drugs are more likely than non-users to experience decreased energy, fatigue upon exertion, or both. The researchers suggest that these findings should be taken into account by doctors when weighing risk versus benefit in prescribing statins.

12 Jun 2012

Atorvastatin News and Research

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Reimbursement systems appear to impact on achievement of cholesterol lowering targets

Study finds that high potency statins can beat dementia

Genetic variations in genes could put patients at risk for statin-associated muscle injury: Study

Stopping cholesterol drugs may increase risk of Parkinson's disease

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

FDA accepts Merck's NDA for NOXAFIL tablets

Coenzyme Q10 offsets cellular changes that are linked to side-effect of some statin drugs: Study

Study evaluates efficacy of drug combinations in treating colorectal cancer

High-dose rosuvastatin reduces acute kidney injury caused by imaging dye in ACS patients

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

FDA acknowledges resubmission of Merck’s NDA for ezetimibe and atorvastatin tablets

Monoclonal antibody boosts cholesterol reduction

Monoclonal antibody boosts cholesterol reduction

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Intensive treatment with high doses of statin drugs shows promise for dyslipidemia

Meijer offers generic Lipitor for free to help families be heart healthy

Statin's potency may cause muscle problems in patients with cardiovascular disease

Dr. Reddy's launches generic LIPITOR tablets in the U.S.

Individuals on statins more likely to experience fatigue with exertion

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News